Tagomics

Tagomics is a Cambridge-based biotech developing a multiomics platform for disease biomarker discovery and diagnostics.

Its platform integrates genomics, epigenomics and fragmentomics with advanced bioinformatics and machine learning to identify disease-associated DNA markers from blood and other biological sources.

Lead applications include early detection of colorectal cancer.

Tagomics has raised £8.3 million across two rounds from investors including Illumina Ventures, IQ Capital and Calculus Capital, and has a co-marketing agreement with Agilent Technologies.